Navigation Links
Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
Date:9/26/2007

EXTON, Pa., Sept. 26 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today reported that the acquisition by Ramius Capital Group, L.L.C. and its affiliates on August 30, 2007 of more than 20 percent of the Company's outstanding common stock, as reported by Ramius in filings with the SEC, constituted a "Change in Control" under the Company's equity compensation plan. As a result, all outstanding unvested stock options, stock appreciation rights and restricted stock held by officers, employees, directors and others under this plan automatically became vested (and, in the case of options and stock appreciation rights, exercisable) in full.

The Company continues to anticipate revenue for the quarter at the high end of its guidance range of $17.0 to $17.7 million. In addition, the Company reiterates its pro forma earnings per share guidance of $0.14, excluding $0.03 per share of remaining charges related to the Company's discontinuance of its embolic protection product platform and prior to the impact of the charges related to this event. The accelerated vesting will result in a non-cash, tax-effected charge of approximately $2.2 million, or $0.19 per share, during the quarter ending September 30, 2007. In addition, the Company will take a non-cash mark-to-market adjustment for the remainder of the quarter on the 284,000 fully vested and exercisable stock appreciation rights. The Company anticipates a reported loss per share of $0.08 including the embolic protection and accelerated vesting charges but prior to the impact of the mark-to-market adjustment. The acceleration will remove all future equity compensation expense related to these stock options and restricted shares under the plan. However, stock appreciation rights will continue to be marked to market on a quarterly basis, as required under Generally Accepted Accounting Principles.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements, including reference to our first quarter fiscal 2008 revenue and earnings guidance, that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "forecast," "believe," or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, the Company's success in launching its endovascular products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling KNC related products in the marketplace, the impact of product recalls and other manufacturing issues, and competition from other technologies, among other important risks. For a more detailed discussion of these and other factors, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Non-GAAP Financial Measures and Reconciliations

We use various numerical measures in conference calls, investor meetings

and other forums which are or may be considered "Non-GAAP financial

measures" under Regulation G. We have provided below for your reference

supplemental financial disclosure for these measures, including the most

directly comparable GAAP measure and an associated reconciliation.

Kensey Nash Corporation

Non-GAAP Financial Measures and Reconciliations

For the Fiscal Year 2008 Quarter Ending September 30, 2007

Forecasted Earnings Per Share Reconciliation

(Unaudited) (Unaudited)

Forecasted As Reported

Three Months Three Months

Ending Ended Year over Year %

September 30, September 30, Change

2007 2006

GAAP diluted loss per share ($0.08) $0.11

Adjustments:

Accelerated vesting of

equity shares 0.19

Discontinuance of embolic

protection platform 0.03 -

Non-GAAP diluted earnings per

share as adjusted $0.14 $0.11 27%

Note: To supplement our forecasted guidance presented in accordance with

GAAP, Kensey Nash Corporation uses non-GAAP measures of as adjusted

earnings per share, which are adjusted from our forecasted GAAP guidance

to exclude certain expenses. These non-GAAP adjustments are provided to

enhance the user's overall understanding of our historical and current

financial performance and our prospects for the future. We believe the

forecasted non-GAAP guidance provides useful information to both

management and investors by excluding certain expenses that we believe are

not indicative of our core operating results.

We have adjusted our forecasted GAAP guidance for the discontinuance of

our embolic protection platform and for the acceleration of vesting. As

previously announced, the Company has and will exclude the impact of

write-offs of inventory, certain dedicated embolic protection equipment,

and other assets related to the Company's decision in June 2007 to

discontinue the embolic protection product line. Additional charges

related to severance and clinical trial closeout costs are expected to be

recorded in the first fiscal quarter of 2008, as set forth in the

reconciliation. In addition, the Company is excluding the impact of the

acceleration of vesting of the equity shares from the first quarter

results as outlined in today's release.

These non-GAAP measures will provide investors and management with an

alternative method for assessing Kensey Nash's operating results in a

manner consistent with future presentation as a result of the

discontinuance of our embolic protection platform. Further, these non-

GAAP results are one of the primary indicators management uses for

planning and forecasting in future periods. The presentation of this

additional information should not be considered in isolation or as a

substitute for results prepared in accordance with accounting principles

generally accepted in the United States.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... IN (PRWEB) , ... December 06, 2016 , ... ... benefits advisory organization, is proud to announce it has added CXC Solutions (CXC) ... benefits management solutions. These solutions are tailored to help benefits advisors reduce ...
(Date:12/6/2016)... ... 2016 , ... METTLER TOLEDO has launched its online ... papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user manuals, ... webinars and videos available online, visit the METTLER TOLEDO Expertise Library . ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... fascinating recount of a powerful woman's story of sacrifice and enlightenment. ... of published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LONDON , Dec. 5, 2016 Spain ... GlobalData,s new report, "Spain Glaucoma Surgery Devices Market ... Spain Glaucoma Surgery Devices market. The report provides value, ... average prices (USD) within market segements - Canaloplasty Micro ... provides company shares and distribution shares data for each ...
(Date:12/5/2016)... , Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., ... presented data from two Phase I trials evaluating ... the 58th annual meeting of the American Society ... California . The two datasets show encouraging ... myeloid leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell ...
(Date:12/5/2016)... 2016  Pennsylvania Physician General Dr. Rachel Levine ... Gary Tennis today filled prescriptions for naloxone, a ... York to demonstrate how anyone ... as a prescription to acquire naloxone at any pharmacy ... remember that any Pennsylvanian can walk up to their ...
Breaking Medicine Technology: